Baidu
map

PLoS One:中国老年人使用他汀类药物的安全性

2016-04-07 徐媛 MedSci原创

与白种人相比,在给定相同剂量的他汀类药物的同时,中国人群血药浓度要比白人高,但是否会增加不良事件,目前尚不知晓。研究人员进行了一项以人群为基础的回顾性队列研究,基于来自加拿大2002年-2013年间安大略省健康医疗数据库的年长人群数据,平均年龄74岁,收纳来自中国参与者19033名,外国参与者57099名,并以1:3的比例按倾向指数法进行配比。研究结果,两组不同人群进行平均1.1年随访,最大随访期

与白种人相比,在给定相同剂量的他汀类药物的同时,中国人群血药浓度要比白人高,但是否会增加不良事件,目前尚不知晓。

研究人员进行了一项以人群为基础的回顾性队列研究,基于来自加拿大2002年-2013年间安大略省健康医疗数据库的年长人群数据,平均年龄74岁,收纳来自中国参与者19033名,外国参与者57099名,并以1:3的比例按倾向指数法进行配比。

研究结果,两组不同人群进行平均1.1年随访,最大随访期长达10.8年,最终结局包括随访结束,参与者死亡,或停用他汀类药物。47%中国人初始剂量大于推荐剂量。和外国参与者相比,中国人并未增加以下任何关于他汀类药物相关严重不良事件:横纹肌溶解症HR0.61(95% CI 0.28 to 1.34), 初发糖尿病HR1.02(95% CI 0.80 to 1.30), 急性肾损伤HR0.90(95% CI 0.72 to 1.13),及全因死亡HR0.88(95% CI 0.74 to 1.05)。在不同类型及剂量的亚组分析中,也得到了相似结果。

以上研究结果表明,在健康状况相似的老年人群中,中国人群与外国人群在他汀类药物不良严重事件发生风险并无显著性差异。药物监管机构应结合现有数据资料(包括该研究结果),判断是否有必要更改中国人他汀类药物推荐剂量。

原始出处

Li DQ1, Kim RB2, McArthur E3, Fleet JL1, Hegele RA4, Shah BR3,5, Weir MA1,3, Molnar AO6, Dixon S3,7, Tu JV3,5, Anand S8, Garg AX1,3.Statin Safety in Chinese: A Population-Based Study of Older Adults.PLoS One. 2016 Mar 8

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789791, encodeId=77ca1e89791dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu May 12 11:53:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044401, encodeId=243120444016e, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Jun 13 06:53:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78297, encodeId=35bfe829778, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:55:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78298, encodeId=576be8298a4, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:55:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76337, encodeId=3b5ee633753, content=学习了,很多血脂高的人呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Thu Apr 07 23:37:00 CST 2016, time=2016-04-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789791, encodeId=77ca1e89791dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu May 12 11:53:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044401, encodeId=243120444016e, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Jun 13 06:53:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78297, encodeId=35bfe829778, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:55:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78298, encodeId=576be8298a4, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:55:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76337, encodeId=3b5ee633753, content=学习了,很多血脂高的人呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Thu Apr 07 23:37:00 CST 2016, time=2016-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789791, encodeId=77ca1e89791dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu May 12 11:53:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044401, encodeId=243120444016e, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Jun 13 06:53:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78297, encodeId=35bfe829778, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:55:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78298, encodeId=576be8298a4, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:55:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76337, encodeId=3b5ee633753, content=学习了,很多血脂高的人呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Thu Apr 07 23:37:00 CST 2016, time=2016-04-07, status=1, ipAttribution=)]
    2016-04-14 李继凯

    文章不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1789791, encodeId=77ca1e89791dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu May 12 11:53:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044401, encodeId=243120444016e, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Jun 13 06:53:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78297, encodeId=35bfe829778, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:55:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78298, encodeId=576be8298a4, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:55:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76337, encodeId=3b5ee633753, content=学习了,很多血脂高的人呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Thu Apr 07 23:37:00 CST 2016, time=2016-04-07, status=1, ipAttribution=)]
    2016-04-14 李继凯

    值得关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1789791, encodeId=77ca1e89791dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu May 12 11:53:00 CST 2016, time=2016-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044401, encodeId=243120444016e, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Jun 13 06:53:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78297, encodeId=35bfe829778, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:55:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78298, encodeId=576be8298a4, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:55:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76337, encodeId=3b5ee633753, content=学习了,很多血脂高的人呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Thu Apr 07 23:37:00 CST 2016, time=2016-04-07, status=1, ipAttribution=)]
    2016-04-07 layyjiangli

    学习了,很多血脂高的人呢

    0

相关资讯

JAMA:心脏手术围手术期接受他汀类药物并不能减少急性肾损伤的发生

根据发表在JAMA的一项研究报告称,接受心脏手术的患者中,手术前后接受高剂量阿托伐他汀治疗与安慰剂相比,并没有减少急性肾损伤的整体风险。这项研究与危重病医学院第四十五急救代表大会的介绍一致。高达30%的患者急性肾损伤(AKI)的并发症可以心脏手术中恢复。他汀类药物影响术后AKI的几种机制。先前的研究已经发现了关于他汀类药物可降低心脏手术患者AKI的混合结果。Frederic T. Billings

AIM:N-乙酰半胱氨酸和他汀类药物可减少造影剂肾病(CIN)

N-乙酰基半胱氨酸,碳酸氢钠,他汀类药物,和抗坏血酸已被研究用于减少造影剂肾病(CIN)。该研究的目的是评估接受造影的成年人中减少CIN干预措施的效果比较。研究人员在2015年6月检索了MEDLINE,EMBASE,Cochrane图书馆,ClinicalTrials.gov,和Scopus数据库。研究的风险偏差和整体证据的综合实力(SOE)被进行了评估。研究人员选择了N-乙酰半胱氨酸,碳酸氢钠,

Circulation:他汀类药物长期降低低密度脂蛋白胆固醇安全性和有效性结果良好

基于他汀类药物的降低低密度脂蛋白(LDL)胆固醇试验后续研究提高了对他汀类药物的安全性和有效性的理解。检查累计心血管事件(疾病总负担)提供了他汀类药物的临床应用更好的价值。本文评估了高风险人群长期治疗后对死亡率和发病率的影响。西苏格兰冠心病预防研究是一项一级预防试验,参与者为45-64岁的高LDL胆固醇男性。6595名男性被随机分配到接受每日一次普伐他汀40毫克或安慰剂,平均4.9年。随后链接到电

Eur J Dent:他汀类药物或可改善高脂血症患者的牙周非手术治疗效果

本研究旨在探讨高血脂患者对牙周非手术治疗的反映效果,以及高血脂患者使用他汀类药物是否会影响牙周非手术治疗的疗效。

Hepatology:他汀类药物可帮助HCV患者降低肝硬化和HCC风险

他汀类药物可延迟慢性丙型肝炎(HCV)患者肝纤维化进展、降低肝细胞性肝癌(HCC)风险。但是最有效的他汀类类型和剂量是什么?研究者进行了一项研究,探究不同类型和剂量的他汀类药物对HCV患者肝纤维化和HCC的影响。研究者通过电子检索的丙肝病毒感染的退伍军人(ERCHIVES)数据库获取了2001-2014年使用抗HCV治疗的所有患者,以及肝硬化和HCC信息。使用累积限定日剂量(cDDD)测定他汀类药

JACC:他汀类药物可减少无症状外周动脉疾病患者的心血管疾病和死亡率

无症状外周动脉疾病患者减少风险的干预措施的功效证据不足。这项研究的目的是评估在这一人群中他汀类药物治疗是否减少主要心血管不良事件(MACE)和死亡率。在2006年到2013年期间,研究人员从加泰罗尼亚初级保健系统的临床记录数据库(SIDIAP)获得了数据。患者年龄在35至85岁,踝肱指数≤0.95,无临床确认的心血管疾病(CVD)。参与者被归类为他汀类药物非使用者或新使用者(首次处方或至少6个月后

Baidu
map
Baidu
map
Baidu
map